![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » DeltaRex-G Secures FDA Authorization as Adjuvant Therapy For TNBC
DeltaRex-G Secures FDA Authorization as Adjuvant Therapy For TNBC
![FDA clears text](https://www.fdanews.com/ext/resources/test/Drug-Images4/FDA-clears.gif?t=1619732616&width=430)
An investigational gene therapy for treatment of triple negative breast cancer (TNBC) developed by the Aveni Foundation and the Cancer Center of Southern California has received FDA authorization as first-line therapy for patients suffering from early-stage disease.
DeltaRex-G was cleared for use under the FDA’s Right to Try program which allows patients to use investigational new drugs and biologics outside of clinical trials.
DeltaRex-G is a tumor-targeted gene therapy that works by starving tumors of their blood supply and destroying cells that build into tumors.
The authorization was supported by results from several early- and mid-stage trials showing the drug had minimal toxicity and could be effective in prolonging life for Stage 4 TNBC patients.
Upcoming Events
-
21Oct